After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Crinetics Pharmaceuticals Inc is $3.16B. A total of 0.99 million shares were traded on the day, compared to an average of 953.18K shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CRNX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, Pizzuti Dana sold 5,000 shares of CRNX for 39.07 per share on Feb 03 ’25. After the transaction, the Chief Med and Dev Officer now owns 31,748 company shares. In a previous transaction on Feb 03 ’25, DANA J PIZZUTI bought 5,000 shares at 39.07 per share.
Among the insiders who sold shares, Pizzuti Dana disposed of 15,000 shares on Jan 03 ’25 at a per-share price of $52.09. This resulted in the Chief Med and Dev Officer holding 29,248 shares of CRNX after the transaction. In another insider transaction, DANA J PIZZUTI bought 15,000 shares at $52.09 per share on Jan 03 ’25.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CRNX in the last 3 months, the mean price target is $76.08 with high estimates of $100.00 and low estimates of $55.00. In terms of 52-week highs and lows, CRNX has a high of $62.53 and a low of $31.84.
As of this writing, CRNX has an earnings estimate of -$0.94 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.56 per share and a lower estimate of -$1.08.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CRNX’s latest balance sheet shows that the firm has $333.71M in Cash & Short Term Investments as of fiscal 2021. There were $3.07M in debt and $15.99M in liabilities at the time. Its Book Value Per Share was $14.26, while its Total Shareholder’s Equity was $331.94M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRNX is Buy with a score of 4.87.
